Revenue Performance - Total revenue for Q4 2024 was $121.6 million, a 50% increase from $81.2 million in Q4 2023[5] - Full year 2024 total revenue reached $441.5 million, an 83% increase compared to $241.6 million in 2023[10] - TransMedics expects total revenue for 2025 to be between $530 million and $552 million, representing 20% to 25% growth compared to 2024[14] Net Income - Net income for Q4 2024 was $6.9 million, or $0.19 per diluted share, compared to $4.0 million in Q4 2023[6] - Full year 2024 net income was $35.5 million, or $1.01 per diluted share, compared to a net loss of $25.0 million in 2023[13] Gross Margin and Operating Expenses - Gross margin for Q4 2024 was 59.2%, slightly up from 59.0% in Q4 2023[7] - Operating expenses for Q4 2024 were $63.4 million, an increase from $45.3 million in Q4 2023, driven by R&D investments[8] Market Performance - The company completed 3,715 U.S. OCS cases in 2024, a 58% increase from 2,347 cases in 2023[6] - OCS market share for 2024 was 20.9%, up from 13.8% in 2023[6] Cash and Assets - Cash as of December 31, 2024, was $336.7 million, compared to $330.1 million as of September 30, 2024[13] - Total assets increased to $804,076 million in 2024 from $706,047 million in 2023, representing a growth of approximately 13.9%[23] Stockholders' Equity - Total stockholders' equity rose significantly to $228,603 million in 2024, up from $137,202 million in 2023, marking an increase of about 66.7%[23] Current Assets and Liabilities - Current assets decreased slightly to $497,216 million in 2024 from $510,654 million in 2023, a decline of approximately 2.5%[23] - Total current liabilities rose to $59,913 million in 2024 from $54,934 million in 2023, an increase of approximately 9.0%[23] Accounts Receivable and Payable - Accounts receivable increased to $97,722 million in 2024, up from $63,576 million in 2023, reflecting a growth of about 53.6%[23] - Accounts payable decreased to $10,292 million in 2024 from $12,717 million in 2023, a decline of approximately 19.1%[23] Debt and Liabilities - Convertible senior notes remained relatively stable at $449,939 million in 2024 compared to $447,140 million in 2023, showing a minimal change[23] - Long-term debt increased slightly to $59,372 million in 2024 from $59,064 million in 2023, indicating a growth of about 0.5%[23] - Operating lease liabilities, net of current portion, decreased to $6,249 million in 2024 from $7,707 million in 2023, a reduction of about 19.0%[23] Inventory - Inventory increased to $46,554 million in 2024 from $44,235 million in 2023, reflecting a growth of approximately 5.2%[23]

Core Insights - TransMedics Group, Inc. reported significant financial growth in 2024, achieving an 83% increase in total revenue year-over-year, driven by the increased utilization of its Organ Care System (OCS) and logistics services [3][8]. Financial Performance - Total revenue for Q4 2024 was $121.6 million, a 50% increase from $81.2 million in Q4 2023, primarily due to higher OCS utilization [4][10]. - Full-year revenue for 2024 reached $441.5 million, up from $241.6 million in 2023, marking an 83% increase [8][10]. - Gross margin for Q4 2024 was 59.2%, slightly up from 59.0% in Q4 2023 [5]. - The gross margin for the full year 2024 was 59.4%, down from 63.8% in 2023, attributed to a higher proportion of service revenue [9]. - Operating expenses for Q4 2024 were $63.4 million, compared to $45.3 million in Q4 2023, driven by increased R&D investments [6][11]. - Net income for Q4 2024 was $6.9 million, or 6% of revenue, compared to $4.0 million in Q4 2023 [7][10]. - For the full year 2024, net income was $35.5 million, or 8% of revenue, compared to a net loss of $25.0 million in 2023 [12][10]. Operational Highlights - TransMedics completed 3,715 U.S. OCS cases in 2024, a 58% increase from 2,347 cases in 2023 [10]. - The company achieved an overall OCS market share of 20.9% across all three organs in 2024, up from 13.8% in 2023 [10]. - As of December 31, 2024, TransMedics owned 19 aircraft and purchased two additional aircraft in 2025 [10]. Future Outlook - For 2025, TransMedics expects total revenue to be in the range of $530 million to $552 million, representing a growth of 20% to 25% compared to 2024 [13].

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of TransMedics investors who were adversely affected by alleged securities fraud between February 28, 2023 and January 10, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/transmedi ...

NEW YORK, Feb. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of TransMedics Group, Inc. (NASDAQ: TMDX).Shareholders who purchased shares of TMDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/transmedics-group-inc-loss-submission-form-2/?id=132354&from=4CLASS PERIOD: Febru ...

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in TransMedics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/transmedics-group-inc. Investors have until April 15, 2025, to ask the Court to be ...

Group 1 - The company aims to invest in firms with strong qualitative attributes, purchasing them at attractive prices based on fundamentals, and holding them indefinitely [1] - The investment strategy focuses on maintaining a concentrated portfolio to avoid underperformers while maximizing exposure to high-potential winners [1] - The company plans to publish articles on selected companies approximately three times a week, including extensive quarterly follow-ups and constant updates [1] Group 2 - The analyst has no current stock, option, or derivative positions in any mentioned companies and does not plan to initiate any within the next 72 hours [2] - The article reflects the analyst's personal opinions and is not influenced by any business relationships with the companies discussed [2]

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons or entities who purchased or otherwise acquired TransMedics Group, Inc. (NASDAQ: TMDX) securities between February 28, 2023 and January 10, 2025. TransMedics describes itself as a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. For more information, submit a form, email attor ...

Core Viewpoint - A class action securities lawsuit has been filed against TransMedics Group, Inc. alleging securities fraud that affected investors between February 28, 2023, and January 10, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [2]. - It is alleged that the company engaged in unsafe practices, concealed safety issues, and lacked proper safety oversight [2]. - The aforementioned actions subjected TransMedics to increased scrutiny and regulatory risk, leading to materially false and misleading statements about its business and operations [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until April 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

RADNOR, Pa., Feb. 24, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against TransMedics Group, Inc. ("TransMedics") (NASDAQ: TMDX) on behalf of those who purchased or otherwise acquired TransMedics securities between February 28, 2023, and January 10, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is April 15, 2025.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered Tran ...

Core Viewpoint - A lawsuit has been filed against TransMedics Group, Inc. and certain senior executives for potential violations of federal securities laws, alleging misrepresentation and fraudulent practices [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Massachusetts, captioned Jewik v. TransMedics Group, Inc. et al, No. 25-cv-10385 [2]. - Investors have until April 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - TransMedics is a commercial-stage medical technology company known for its "Organ Care System" (OCS), which maintains donor organs' viability before transplant [3]. Group 3: Allegations - The complaint alleges that TransMedics misrepresented its business practices, claiming they were driven by kickbacks, fraudulent overbilling, and coercive tactics [4]. - It is further alleged that the company engaged in unsafe practices involving OCS, concealed safety issues, and lacked proper safety oversight [4]. Group 4: Stock Performance - Following allegations of misconduct from U.S. Representative Paul Gosar, TransMedics' stock price fell approximately 4%, from $86.99 on February 21, 2024, to $83.14 on February 23, 2024 [5]. - After a report from Scorpion Capital on January 10, 2025, which accused TransMedics of anti-competitive schemes and billing fraud, the stock price declined an additional 5%, from $72.55 on January 8, 2025, to $68.81 on January 10, 2025 [6].